Pyridine

Pyridine

SCHEMBL21497058

C1CNC1.c1ccncc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
NAPRT Q6XQN6 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
CHRNB2 P17787 7/20 0.39
CHRNA4 P43681 7/20 0.39
SMN1; SMN2 Q16637 2/20 0.33
CXCR4 P61073 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ADRB2 P07550 1/20 0.32
NCF1 P14598 1/20 0.32
PLD1 Q13393 1/20 0.32
CHRNA7 P36544 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
NOTUM Q6P988 1/20 0.30
MEN1 O00255 2/20 0.30
CYP2D6 P10635 2/20 0.30
CYP2C19 P33261 2/20 0.30
KMT2A Q03164 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL812392 0.94 TSHR (0.53) TSHRNAPRTTDP1CHRNB2CHRNA4
Pyridine SCHEMBL28057559 0.91 TSHR (0.50) TSHRNAPRTTDP1CHRNB2CHRNA4
Pyridine SCHEMBL5210014 0.91 CXCR4 (0.50) TSHRNAPRTTDP1CHRNB2CHRNA4
Pyridine SCHEMBL8406615 0.91 CXCR4 (0.50) TSHRNAPRTTDP1CHRNB2CHRNA4
Piperidine SCHEMBL2420379 0.91 ALDH1A1 (0.50) TSHRNAPRTTDP1CHRNB2CHRNA4
Pyridine SCHEMBL11825162 0.90
Piperidine SCHEMBL28040221 0.89 ALDH1A1 (0.47) TSHRNAPRTTDP1CHRNB2CHRNA4
Piperidine SCHEMBL27535943 0.89 ALDH1A1 (0.47) TSHRNAPRTTDP1CHRNB2CHRNA4
Piperazine SCHEMBL1699696 0.87 TSHR (0.60) TSHRNAPRTTDP1CHRNB2CHRNA4
Pyridine SCHEMBL29286575 0.87 TSHR (0.60) TSHRNAPRTTDP1CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230121082-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-04-20 US disclosed
US-20210101884-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2021-04-08 US disclosed
WO-2019204740-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210101884-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES DGKA, DGKK, PRKG2 TSHR 2832/4885NAPRT 3940/4885TDP1 2471/4885
US-20230121082-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES DGKA, DGKK, PRKG2 TSHR 2832/4885NAPRT 3940/4885TDP1 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.